Literature DB >> 15647752

Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.

Jeffery A Lieberman1, Joel Greenhouse, Robert M Hamer, K Ranga Krishnan, Charles B Nemeroff, David V Sheehan, Michael E Thase, Martin B Keller.   

Abstract

With increasing numbers of treatment options available for patients with major depression over the last decade and the growing body of evidence describing their efficacy and safety, clinicians often find it difficult to determine the best and most appropriate evidence-based treatment for each patient. Systematic reviews utilizing statistical methods that synthesize and evaluate data from a number of studies have become increasingly more available over the past decade. We review major findings and lessons learned from salient examples of quantitative analyses of antidepressant research and provide recommendations for meta-analysts, journal and grant reviewers, and research 'consumers' (ie, clinicians) for conducting, reporting, and evaluating such analyses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647752     DOI: 10.1038/sj.npp.1300571

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  20 in total

1.  How close is evidence to truth in evidence-based treatment of mental disorders?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11-22       Impact factor: 5.270

Review 2.  [Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making].

Authors:  H-J Möller; W Maier
Journal:  Nervenarzt       Date:  2007-09       Impact factor: 1.214

3.  Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis.

Authors:  S Weinmann; T Becker; M Koesters
Journal:  Psychopharmacology (Berl)       Date:  2007-10-23       Impact factor: 4.530

Review 4.  Do antidepressants really work? A clinicians' guide to evaluating the evidence.

Authors:  Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

5.  Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.

Authors:  Hans-Jürgen Möller; Wolfgang Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

6.  Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.

Authors:  Sidney H Kennedy; Henning F Andersen; Raymond W Lam
Journal:  J Psychiatry Neurosci       Date:  2006-03       Impact factor: 6.186

7.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Introduction and Methods.

Authors:  Raymond W Lam; Sidney H Kennedy; Sagar V Parikh; Glenda M MacQueen; Roumen V Milev; Arun V Ravindran
Journal:  Can J Psychiatry       Date:  2016-08-02       Impact factor: 4.356

8.  A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.

Authors:  Graham J Emslie; Apurva Prakash; Qi Zhang; Beth A Pangallo; Mark E Bangs; John S March
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-09       Impact factor: 2.576

Review 9.  Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials.

Authors:  Dorian Deshauer; David Moher; Dean Fergusson; Ester Moher; Margaret Sampson; Jeremy Grimshaw
Journal:  CMAJ       Date:  2008-05-06       Impact factor: 8.262

10.  The impact of analytic method on interpretation of outcomes in longitudinal clinical trials.

Authors:  A Prakash; R C Risser; C H Mallinckrodt
Journal:  Int J Clin Pract       Date:  2008-06-28       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.